Lilly posts Phase 2b retatrutide renal results; registers tersolisib kidney PK studyNov 13Weekly roundup, 10 itemsabemaciclibanastrozole
Altimmune reports Q3 2026 results as pemvidutide programs advance in MASH and AUDNov 12Quarterly updateAltimmune, Inc.MetaVia Inc.
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Lilly raises 2026 revenue guidance to $85-87 billion on Mounjaro, Zepbound growthAug 5Quarterly updateEli Lillytirzepatide